中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.022 seconds)

    New conjugates of ancrod and polyalkylene glycols - for treatment of Myocardial infarction, stroke, thrombosis etc., have longer half-life than ancrod alone
    6.
    发明专利
    New conjugates of ancrod and polyalkylene glycols - for treatment of Myocardial infarction, stroke, thrombosis etc., have longer half-life than ancrod alone 未知

    公开(公告)号：DE4041570A1

    公开(公告)日：1992-06-25

    申请号：DE4041570

    申请日：1990-12-22

    Applicant: BASF AG

    Inventor： STRUBE KARL-HERMANN DR ,  SCHWEDEN JUERGEN DR ,  BALDINGER VERENA DR ,  SCHWARZ MARGARETE DR

    IPC: A61K38/00 ,  C12N9/64

    Abstract: Protein-polyalkyleneglycol derivs. of formula (A-(CH2)n-(O-(CH2)q)m-B-))pX (I) are new, where A is OH, NH2, NHCOR, OR or OCOR; R is 1-4C alkyl; n is 2, 3 or 4; m is 30-500; q is 2, 3 or 4; B is a direct bond or a linker; p is 1-10; X is a polypeptide with anerod activity which is bound via NH2 gp(s).. The polyalkylene glycol is pref. a polyethyleneglycol with a mol. wt. of 1500-15000 D.a. The protein component is anerod or anerod in which aminoacids 1-105 have been exchanged. (I) is prepd. by mixing both components in soln.. USE/ADVANTAGE - (I) Like anerod (an enzyme isolated from Agkistrodon rhodostomer) acts as a fibrinogen cleaving agent. It thus has anticoagulant properties, and can be used to treat e.g. glomeralonephritis, coronary infarction, non-ischaemic stroke, peripheral arterial circulation disorders (e.g. atherosclerosis, thromangikis and diabetic microangiopathy), angina pectoris, thromboses, and rethromboses, e.g. after surgery to implant arterial and venous prostheses. (I) Have longer half-life, better activity, immunogenicity and stability, and are more suitable for therapeutic use than anerod.

Patent Agency Ranking